Skip to main content
Premium Trial:

Request an Annual Quote

Big Pharma Needs Luck

Deepak Singh at bbgm ponders an article he read in the Financial Times that pairs drug discovery and serendipity. There is a role for serendipity in drug discovery, but the declining productivity of the pharma industry is not necessarily due to lazy scientists who can't innovate, he says. Systems biology is tough -- and managing and understanding all the data from these experiments is no easy task. "I will agree on one thing, though; pharma has to move away from rigid planning faster and towards the proof of concept/first in man approaches that many are now beginning to take," he writes.

To add flames to the fire, In the Pipeline reports on more layoffs at GSK, this time in the oncology group, by about 40 percent of its staff. "It looks like the company is moving one by one through its Centers of Excellence in Drug Discovery (CEDDs) and running a most excellent scythe through them," writes Derek Lowe.

 

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.